Latest News

Exclusive Interviews

Browse by Company

  • All
  • AIkido Pharma
  • Aion Therapeutic
  • Albert Labs
  • Aleafia Health
  • Algernon Pharmaceuticals
  • Alphamind
  • Atai Life Sciences
  • Atma Journeys
  • AWAKN
  • Beckley Psytech
  • Better Plant Sciences
  • BetterLife Pharma
  • Bexson Biomedical
  • Braxia Scientific
  • Bright Minds Biosciences
  • Brightmind
  • Buzz Capital
  • CaaMTech
  • CannaGlobal Wellness
  • CB Therapeutics
  • CBDV
  • Champignon Brands
  • Clerkenwell Health
  • Compass Pathways
  • Cybin Corp
  • Delic Corp
  • Delix Therapuetics
  • DemeRx
  • Diamond Therapeutics
  • Ehave
  • Ei Foundation
  • Ei Ventures
  • Eleusian Biosciences
  • Eleusis
  • Empower Clinics
  • Entheon Biomedical
  • Entheos Foundation
  • Field Trip Health
  • Filament Health
  • Fireside Project
  • GH Research
  • GreenStar Biosciences
  • Havn Life
  • Hollister Biosciences
  • IntelGenx
  • Levitee Labs
  • Liberty Leaf
  • Lobe Sciences
  • MagicMed
  • MAPS
  • Mind Cure
  • Mindleap
  • MindMed
  • Mindset Pharma
  • Mota Ventures
  • Mycrodose Therapeutics
  • Mydecine
  • MYND Life Sciences
  • NeonMind
  • New Wave
  • NewLeaf Brands
  • Noetic Foundry
  • Nova Mentis
  • Nova Mentis Biotech
  • Novamind
  • Numinus
  • Nutritional High
  • NYU Langone Health
  • Octarine Bio
  • Optimi Health
  • Orthogonal Thinker
  • Osmond Labs
  • Osoyoos
  • Pharmadrug
  • Pharmather
  • Pilz Bioscience
  • PSFC
  • Psilera Bioscience
  • PsyBio
  • Psyched Wellness
  • Psyence Group
  • Psygen
  • PSYK
  • Pure Extracts
  • Red Light Holland
  • Reset Pharma
  • Revive Therapeutics
  • Silo Pharma
  • Silo Wellness
  • Small Pharma
  • SYNTAC Institute
  • Synthesis Institute
  • The Lundquist Institute
  • TheraPsil
  • Thoughtful Brands
  • Tryp Therapeutics
  • Unlimited Sciences
  • Usona Institute
  • Wesana Health
  • Wuhan General Group
  • Yield Growth Corp
All
  • All
  • AIkido Pharma
  • Aion Therapeutic
  • Albert Labs
  • Aleafia Health
  • Algernon Pharmaceuticals
  • Alphamind
  • Atai Life Sciences
  • Atma Journeys
  • AWAKN
  • Beckley Psytech
  • Better Plant Sciences
  • BetterLife Pharma
  • Bexson Biomedical
  • Braxia Scientific
  • Bright Minds Biosciences
  • Brightmind
  • Buzz Capital
  • CaaMTech
  • CannaGlobal Wellness
  • CB Therapeutics
  • CBDV
  • Champignon Brands
  • Clerkenwell Health
  • Compass Pathways
  • Cybin Corp
  • Delic Corp
  • Delix Therapuetics
  • DemeRx
  • Diamond Therapeutics
  • Ehave
  • Ei Foundation
  • Ei Ventures
  • Eleusian Biosciences
  • Eleusis
  • Empower Clinics
  • Entheon Biomedical
  • Entheos Foundation
  • Field Trip Health
  • Filament Health
  • Fireside Project
  • GH Research
  • GreenStar Biosciences
  • Havn Life
  • Hollister Biosciences
  • IntelGenx
  • Levitee Labs
  • Liberty Leaf
  • Lobe Sciences
  • MagicMed
  • MAPS
  • Mind Cure
  • Mindleap
  • MindMed
  • Mindset Pharma
  • Mota Ventures
  • Mycrodose Therapeutics
  • Mydecine
  • MYND Life Sciences
  • NeonMind
  • New Wave
  • NewLeaf Brands
  • Noetic Foundry
  • Nova Mentis
  • Nova Mentis Biotech
  • Novamind
  • Numinus
  • Nutritional High
  • NYU Langone Health
  • Octarine Bio
  • Optimi Health
  • Orthogonal Thinker
  • Osmond Labs
  • Osoyoos
  • Pharmadrug
  • Pharmather
  • Pilz Bioscience
  • PSFC
  • Psilera Bioscience
  • PsyBio
  • Psyched Wellness
  • Psyence Group
  • Psygen
  • PSYK
  • Pure Extracts
  • Red Light Holland
  • Reset Pharma
  • Revive Therapeutics
  • Silo Pharma
  • Silo Wellness
  • Small Pharma
  • SYNTAC Institute
  • Synthesis Institute
  • The Lundquist Institute
  • TheraPsil
  • Thoughtful Brands
  • Tryp Therapeutics
  • Unlimited Sciences
  • Usona Institute
  • Wesana Health
  • Wuhan General Group
  • Yield Growth Corp
MYND Life Sciences PR
Press Release

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd.

PharmaTher PR
Press Release

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

Lobe Sciences PR
Press Release

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Psygen Press Release
Press Release

Psygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio

Mydecine Press Release
Press Release

Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson

MindMed News
Press Release

MindMed Announces Strategic Research Collaboration with Sphere Health

Lobe Sciences PR
Press Release

Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD

Weekly Psychedelic Bulletin
Psychedelic Investment Bulletin

Psychedelic Bulletin: Delix Raises $70m Series A; Toronto Gets Psychedelics Research Centre; Elon Musk Endorses Psychedelics